Analysis of Bromocriptine in the Treatment of Polycystic Ovary Syndrome: A Systematic Review

Objective To assess the effectiveness and safety of bromocriptine in women with infertility, caused by polycystic ovary syndrome. Methods Pubmed database, the Cochrane Library, the Embase database, the CNKI database, the VIP database, the CBM database and the Wanfang database were searched to identify relevant randomized controlled trials(RCTs) from the day of database builded to August 2017. RCTs which met the inclusion criteria were selected, reviewed and analysised by Revman 5.0 software. Results Six RCTs involving 469 patients were included in this study, 231 patients in the bromocriptine group and 238 patients in the control group. Meta-analysis results showed that the rates of ovulation(Z=0.20, P=0.84), pregnancy(Z=1.88, P=0.06), follicular development(Z=0.51, P=0.61) and abortion(Z=0.98, P=0.33) did not differ significantly among the groups. However, the mature follicle(Z=3.62, P=0.000 3) and the endometrial thickness(Z=2.77, P=0.006) were significantly greater in the bromocriptine group than those in control group. Conclusion It is found that no evidence suggesting that bromocriptine improves the rates of ovulation, pregnancy, follicular development and abortion, though it showed benefit in terms of mature follicle and endometrial thickness. Limitations included imprecision(small design trials) and poor reporting of study methods. Large, well-designed RCTs are necessary to further evaluate the role of bromocriptine in polycystic ovary syndrome.